nach oben

Reactions Weekly

Erschienen in:

01.04.2023 | Case report

Docetaxel/plasma/vitamin-K

Acquired factor V inhibitor and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Kodama K, et al. Bleeding due to acquired factor V inhibitor successfully treated with platelet transfusion during treatment for recurrent prostate squamous cell carcinoma. Rinsho Ketsueki 63: 1508-1512, No. 11, Jan 2022. Available from: URL: http://doi.org/10.11406/rinketsu.63.1508 [Japanese; summarised from a translation]

Titel: Docetaxel/plasma/vitamin-K
Acquired factor V inhibitor and lack of efficacy: case report
Publikationsdatum: 01.04.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-36906-3

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Docetaxel/plasma/vitamin-K

Acquired factor V inhibitor and lack of efficacy: case report

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Morphine

Mometasone

Pembrolizumab

Immunosuppressants

Antibacterials/corticosteroids

Calcipotriol/corticosteroids/fluorouracil